929016-96-6

Basic information

• Product Name: SB939
• Synonyms: SB939;(2E)-3-[2-Butyl-1-[2-(diethylaMino)ethyl]-1H-benziMidazol-5-yl]-N-hydroxy-2-propenaMide;(2E)-3-[2-Butyl-1-[2-(diethylaMino)ethyl]-1H-benziMidazol-5-yl]-N-hydroxyacrylaMide;(E)-3-[2-Butyl-1-(2-diethylaMinoethyl)-1H-benziMidazol-5-yl]-N-hydroxy-2-propenaMide;KaeMpferol 3-O-β-D-(6-E-p-CouMaroylglucoside);Pracinostat;Pracinostat (SB939);(2E)-3-[2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxyacrylamide Pracinostat (SB939)
• CAS NO: 929016-96-6
• Molecular Formula: C20H30N4O2
• Molecular Weight: 358.4778
• Product Categories: Amines;Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitor
• Mol File: 929016-96-6.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.11
• Solubility: insoluble in H2O; ≥11.4 mg/mL in DMSO; ≥24.8 mg/mL in EtOH with ultrasonic
• PKA: 8.67±0.23(Predicted)
• CAS DataBase Reference: SB939(CAS DataBase Reference)
• NIST Chemistry Reference: SB939(929016-96-6)
• EPA Substance Registry System: SB939(929016-96-6)

Safety Data

• Hazardous Substances Data: 929016-96-6(Hazardous Substances Data)

Usage

Description

SB939 is a potent and orally active histone deacetylase (HDAC) inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. It selectively targets tumor tissues, making it a promising therapeutic candidate for use in patients with advanced solid malignancies.

Uses

Used in Oncology:
SB939 is used as a potent histone deacetylase inhibitor for the treatment of advanced solid malignancies. Its selectivity for tumor tissues and high efficacy in mouse models of colorectal cancer make it a promising therapeutic candidate for patients with such conditions.
Used in Drug Development:
SB939 is used in the development of novel drug delivery systems to enhance its applications and efficacy against cancer cells. Various organic and metallic nanoparticles can be employed as carriers for SB939 delivery, aiming to improve its delivery, bioavailability, and therapeutic outcomes.

Biological Activity

pracinostat, also known as sb939, is a potent and orally available inhibitor of histone deacetylase (hdac) with a relatively stronger selectivity (more than 1000-fold) for class i, class ii and class iv hdacs rather than class iii hdacs. pracinostat potently suppresses proliferation in a wide range of cancer cell lines, including colon cancer, ovarian cancer, prostate carcinomas, acute myeloid leukaemia (aml) and b cell lymphoma. recent study results have shown that sb939 induces the accumulation of acetylated histone h3 (ach3) and acetylated α-tubulin and increases the expression of the cyclin dependent kinase inhibitor p21 in cancer cells.razak ar, hotte sj, siu ll, chen ex, hirte hw, powers j, walsh w, stayner la, laughlin a, novotny-diermayr v, zhu j, eisenhauer ea. phase i clinical, pharmacokinetic and pharmacodynamic study of sb939, an oral histone deacetylase (hdac) inhibitor, in patients with advanced solid tumours. br j cancer. 2011;104(5):756-762.